舒肝解郁胶囊联合阿立哌唑治疗精神分裂症的效果及对氧化应激水平的影响

Effect of Shugan Jieyu Capsules combined with Aripiprazole in the treatment of schizophrenia and its influence on the levels of oxidative stress

目的观察舒肝解郁胶囊联合阿立哌唑治疗精神分裂症的效果及对氧化应激水平的影响。方法选取2018年1~12月我院收治的确诊为精神分裂症的80例患者作为研究对象,按照随机原则将其分为对照组与观察组,每组各40例。对照组患者口服阿立哌唑治疗,观察组患者口服舒肝解郁胶囊联合阿立哌唑治疗。观察两组患者治疗前后的阳性和阴性症状量表(PANSS)评分、氧化应激指标[总超氧化物歧化酶(T-SOD)、谷胱甘肽过氧化物酶(GSH-Px)、过氧化氢酶(CAT)]水平,并比较两组患者的治疗总有效率。结果两组患者治疗前的各项PANSS评分比较,差异无统计学意义(P>0.05);两组患者治疗8周后的各项PANSS评分均低于治疗前,差异有统计学意义(P<0.05);观察组患者治疗8周后的阴性症状评分明显低于对照组,差异有统计学意义(P<0.05)。两组患者的治疗总有效率比较,差异无统计学意义(P>0.05)。治疗前,两组患者的血清T-SOD、GSH-Px、CAT水平比较,差异无统计学意义(P>0.05);治疗后,两组患者的血清T-SOD、GSH-Px水平均高于治疗前,CAT水平显著低于治疗前,差异有统计学意义(P<0.05);观察组患者治疗后的血清T-SOD、GSH-Px水平均高于对照组,CAT水平低于对照组,差异有统计学意义(P<0.05)。结论舒肝解郁胶囊联合阿立哌唑可有效改善精神分裂症患者的临床症状,有助于患者氧化应激能力的提升。

Objective To observe the effect of Shugan Jieyu Capsules combined with Aripiprazole in the treatment of schizophrenia and its influence on the levels of oxidative stress. Methods A total of 80 patients diagnosed with schizophrenia and treated in our hospital from January to December 2018 were selected as research objects, and they were divided into the control group and the observation group according to the random principle, 40 cases in each group. The control group was treated with Aripiprazole orally, while the patients in the observation group were treated with Shugan Jieyu Capsules combined with Aripiprazole orally. The positive and negative symptom scale(PANSS) scores and the levels of oxidative stress indicators(total superoxide dismutase [T-SOD], glutathione peroxidase [GSH-Px], catalase [CAT])before and after treatment were observed between the two groups. The total effective rate of treatment was compared between the two groups of patients. Results There were no significant differences in the PANSS scores between the two groups before treatment(P>0.05). The PANSS scores of the two groups after 8 weeks of treatment were lower than those before treatment, and the differences were statistically significant(P<0.05). The score of negative symptoms in the observation group was significantly lower than that in the control group after 8 weeks of treatment, and the difference was statistically significant(P<0.05). There was no significant difference in the total effective rate of treatment between the two groups (P>0.05). There were no significant differences in serum levels of T-SOD, GSH-Px and CAT between the two groups before treatment(P>0.05). After treatment, the serum levels of T-SOD and GSH-Px in the two groups were higher than those before treatment, and the CAT level was significantly lower than that before treatment, with statistically significant differences(P<0.05). The serum levels of T-SOD and GSH-Px in the observation group after treatment were higher than those in the control group, and the CAT level was lower than that in the control group, with statistically significant differences(P<0.05). Conclusion Shugan Jieyu Capsules combined with Aripiprazole can effectively improve the clinical symptoms of schizophrenia patients and help to enhance the oxidative stress ability of patients.